Expert Rev Neurother. 2009;9(12):1713-1725. The first patients with squint were successfully treated in 1977 [17] and since then botulinum toxin type A delivered by local injection has been used in ...

14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and ...

Ipsen has announced the presentation of new study data on Dysport (abobotulinumtoxinA) in stroke and other neurological ...

Botulinum toxin therapy has emerged as a pivotal treatment in the management of spasticity, a debilitating neuromuscular condition characterised by increased muscle tone and hyperactive reflexes. By ...